Financials in USD. Standardized financial statements.
A compact view of how Bellevue Life Sciences Acquisition Corp. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $2.91M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $2.31M | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $592,905 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +20.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $18.93M | $3.52M | $1.83M | $35,388 | $3,308 | $23,812 |
| Operating Income? | -$18.34M | -$3.52M | -$1.83M | -$35,388 | -$3,308 | -$23,810 |
| EBITDA? | -$18.34M | -$3.52M | $3.72M | $193,097 | $233,250 | -$23,810 |
| Income Before Tax | -$28.89M | -$2.12M | $944,591 | -$35,388 | -$3,308 | -$23,812 |
| Income Tax Expense | $0 | -$296,000 | $540,811 | $0 | $0 | $0 |
| Net Income? | -$28.89M | -$2.41M | $403,780 | -$35,388 | -$3,308 | -$23,812 |
| EPS? | $0.00 | $-0.54 | $0.07 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $0.00 | $-0.54 | $0.07 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality